What Is Suboxone? A Clinical Guide to Buprenorphine

Suboxone is a prescription medication that combines buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist, and is FDA-approved to treat opioid use disorder (OUD) as part of a complete treatment plan that also includes counseling and psychosocial support. According to the National Institute on Drug Abuse (NIDA), buprenorphine-based medications like Suboxone reduce opioid use, ease withdrawal, and lower the risk of fatal overdose when taken as prescribed.

At Clear Steps Recovery, our medical team uses Suboxone within a structured Medication-Assisted Treatment (MAT) program — medication paired with therapy, medical monitoring, and long-term support. This guide explains what Suboxone is, how it works, what starting treatment looks like, and how it compares with other FDA-approved medications for opioid use disorder.

What is Suboxone?

Suboxone is a fixed-dose combination medication containing buprenorphine and naloxone, formulated either as a sublingual film that dissolves under the tongue or a sublingual tablet. It was first approved by the U.S. Food and Drug Administration in 2002 for the treatment of opioid dependence and today is one of the most widely prescribed medications for opioid use disorder in the United States (SAMHSA, 2024). The buprenorphine component is active against cravings and withdrawal; the naloxone component is added primarily as an anti-misuse deterrent — it remains largely inactive when the film or tablet is used correctly, but causes precipitated withdrawal if the medication is crushed and injected.

Suboxone is a Schedule III controlled substance. Since passage of the Consolidated Appropriations Act of 2023, the federal DATA 2000 "X-waiver" is no longer required to prescribe it. Any clinician with Schedule III prescribing authority — physicians, nurse practitioners, and physician assistants — can now prescribe buprenorphine for opioid use disorder (SAMHSA, 2024).

Film vs. tablet

Clinically, both formulations deliver the same active ingredients, but many patients prefer the film because it dissolves faster and is individually packaged for consistent dosing. The tablet is sometimes chosen for cost reasons when generic options are available. Either formulation must be placed under the tongue or inside the cheek and held there without chewing or swallowing until fully dissolved — swallowing the medication reduces effectiveness because buprenorphine is poorly absorbed through the stomach.

How does Suboxone work?

Suboxone works by occupying the same mu-opioid receptors in the brain that are activated by opioids like heroin, fentanyl, oxycodone, and hydrocodone — but it activates them only partially. Buprenorphine is classified as a partial opioid agonist, meaning it produces a milder, capped opioid effect compared with full agonists. According to NIDA's 2024 research, this partial activation is enough to suppress withdrawal symptoms and cravings, without producing the intense euphoria or respiratory depression associated with full opioid agonists. Buprenorphine also has very high binding affinity at the mu receptor, meaning it displaces other opioids and blocks them from attaching — part of why people on Suboxone are protected from overdose on other opioids. The naloxone component is an opioid antagonist that is largely inactive when Suboxone is taken sublingually as prescribed; it becomes active only if someone attempts to inject the medication, where it precipitates immediate withdrawal.

The ceiling effect

Unlike methadone and heroin, buprenorphine has a pharmacological "ceiling effect" — beyond a certain dose, its opioid effects (including respiratory depression) plateau rather than continuing to increase. This ceiling makes buprenorphine significantly safer in overdose than full agonists, particularly when taken alone. The ceiling does not apply when buprenorphine is combined with other central nervous system depressants like benzodiazepines or alcohol, which is why prescribers carefully review all other medications and substances during assessment.

Who is Suboxone for?

Suboxone is indicated for adults diagnosed with opioid use disorder, typically those with moderate-to-severe OUD as defined by the DSM-5 criteria from the American Psychiatric Association. A person may be a good candidate for Suboxone if they have developed physical dependence on opioids — whether from prescribed pain medication, heroin, or illicit fentanyl — and want medical support to stop using. According to SAMHSA's 2024 treatment improvement guidance, buprenorphine-based medications are appropriate for most adults with OUD, including pregnant patients (where buprenorphine alone, without naloxone, may be preferred), people with co-occurring mental health conditions, and those who have tried abstinence-based approaches without success. Candidacy is determined by a licensed prescriber after a full clinical assessment. Patients with severe liver disease, active benzodiazepine misuse, or certain allergies may need an alternative approach.

When it may not be the right fit

Suboxone is not usually a first choice for people who have not yet developed physical dependence on opioids, for patients with specific medical contraindications, or for those whose clinical team recommends methadone (for example, individuals with very high opioid tolerance, long histories of treatment, or unstable housing that makes daily clinic visits more feasible than home-based dosing). Extended-release naltrexone (Vivitrol) is another FDA-approved option that may be preferred for patients who are already opioid-free and want a non-opioid blocker rather than a partial agonist — see our guide to top medications for addiction treatment.

What does starting Suboxone look like?

Starting Suboxone — a process clinicians call induction — begins only after a person is in moderate opioid withdrawal. That timing matters: if Suboxone is started while other opioids are still active in the body, buprenorphine's high receptor affinity can displace them and trigger precipitated withdrawal, which is rapid-onset, intense, and distressing. According to SAMHSA's Buprenorphine Quick Start Pocket Guide, the first dose is typically given when objective signs of withdrawal — pupillary dilation, sweating, tremor, elevated heart rate — are clearly present, often 12–24 hours after the last short-acting opioid. Induction may happen in the prescriber's office, in the emergency department, or, increasingly, at home with clinician support via telehealth (a flexibility permanently expanded by SAMHSA in 2024). Your Clear Steps Recovery prescriber will tailor the specific dosing schedule to your history, substance type, and withdrawal severity — no two inductions are identical.

What the first few days feel like

Most patients notice relief from cravings and withdrawal within 30–60 minutes of their first properly-timed dose. The first week is typically the most variable — some patients need dose adjustments over several days to reach steady symptom control. Common early-week experiences include mild headaches, sleep disruption, and gastrointestinal changes as the body stabilizes. Stay in close contact with your prescriber during this window so doses can be titrated based on how you feel, not on a rigid schedule.

How long do people take Suboxone?

There is no universal duration for Suboxone treatment. Current clinical consensus, reflected in guidance from NIDA, SAMHSA, and the American Society of Addiction Medicine (ASAM), is that MAT for opioid use disorder should continue as long as it is clinically beneficial — which for many patients means months or years, and for some, indefinitely. The 2024 NIDA review found that patients on maintenance buprenorphine have substantially lower overdose and all-cause mortality rates than those who taper off early, and that retention in treatment beyond 12 months is associated with the best long-term outcomes. Decisions about tapering are made collaboratively between patient and prescriber, usually only after sustained stability in other life domains (housing, employment, relationships, co-occurring mental health care). Framing Suboxone as a short-term bridge rather than a chronic-disease medication is a common mistake; opioid use disorder is a chronic, relapsing brain disease, and maintenance medication is evidence-based long-term care.

What are common side effects?

Most Suboxone side effects are mild and resolve as the body adjusts. According to the FDA-approved prescribing information, the most commonly reported effects include headache, constipation, nausea, insomnia, sweating, and oral numbness or redness at the site of film placement. Because buprenorphine is an opioid, it can cause respiratory depression, particularly when combined with other CNS depressants — the FDA boxed warning highlights the danger of combining Suboxone with benzodiazepines, alcohol, or other sedating medications. Rare but serious side effects include hepatic (liver) effects, allergic reactions, adrenal insufficiency with long-term use, and hyponatremia. Patients with liver disease need baseline liver function tests and periodic monitoring. Always disclose your full medication list — including over-the-counter products, supplements, and any substances you are using — to your prescriber, because interactions are the main driver of preventable adverse events.

What to do about dental effects

In 2022, the FDA added a warning about dental problems — cavities, enamel erosion, and tooth loss — associated with buprenorphine films and tablets because the medication sits in the mouth as it dissolves. To reduce risk: rinse your mouth with water after the medication has fully dissolved (do not swallow the water immediately), wait at least an hour before brushing teeth, and maintain routine dental care. Mention Suboxone to your dentist so they can monitor for early changes.

What does the research say about outcomes?

The evidence base for buprenorphine in opioid use disorder is substantial and consistent across decades of research. According to NIDA's research report on medications for opioid use disorder, patients on adequately dosed buprenorphine are approximately 1.82 times more likely to remain in treatment than those on placebo. A 2024 Medicare cohort study cited by NIDA found 52% lower odds of fatal overdose among people receiving buprenorphine compared with those receiving no medication after a nonfatal overdose. Higher daily doses (in the 16–24 mg range) are associated with longer retention and fewer subsequent emergency visits than lower doses, and doses above 24 mg have been shown safe and sometimes beneficial for patients with high fentanyl tolerance. Results published in JAMA Psychiatry and the New England Journal of Medicine consistently show that MAT with buprenorphine outperforms detox-plus-counseling alone across every measured outcome — retention, illicit opioid use, overdose mortality, infectious disease acquisition, and quality of life. These are population-level findings; individual outcomes depend on the right medication, the right dose, and wraparound clinical support.

How does MAT integrate with counseling?

MAT is not medication instead of therapy — it is medication and therapy. Federal guidance from SAMHSA and clinical best practice from ASAM both require that medications like Suboxone be offered alongside behavioral health services. At Clear Steps Recovery, that typically means weekly individual therapy, group therapy focused on relapse prevention and coping skills, family counseling when appropriate, and case management connecting patients to housing, legal, or employment resources. Read more in our article on success stories from MAT participants, which documents real outcomes from structured medication-plus-therapy programs.

How is Suboxone different from methadone or naltrexone?

Suboxone, methadone, and naltrexone are the three primary FDA-approved medications for opioid use disorder — all evidence-based, all effective, but different in mechanism and delivery. Methadone is a full opioid agonist; it fully activates opioid receptors and is dispensed only through SAMHSA-certified Opioid Treatment Programs (OTPs), typically requiring daily clinic visits in the early phase. Suboxone is a partial agonist that can be prescribed in primary care or specialty addiction medicine settings and taken at home. Naltrexone (brand name Vivitrol as the monthly injection) is an opioid antagonist — it blocks opioid receptors entirely and carries no dependence potential, but requires full detoxification before starting, which is a barrier for many patients. Research cited by Harvard Health and summarized in the 2024 NIDA research report found no significant difference between methadone and buprenorphine at adequate doses in reducing illicit opioid use, while extended-release naltrexone showed meaningfully lower initiation rates than buprenorphine (about 72% vs. 94%). Which medication is "right" depends on a patient's clinical picture, goals, and access to care — this is a decision best made with a prescriber.

Is Suboxone safe during pregnancy?

Yes, buprenorphine is considered a safer option than continued illicit opioid use during pregnancy and is recommended by SAMHSA, ACOG, and NIDA for pregnant patients with opioid use disorder. During pregnancy, many clinicians prefer buprenorphine alone (Subutex) rather than the buprenorphine-naloxone combination (Suboxone), to minimize fetal exposure to naloxone — though current evidence suggests both formulations are reasonable when Subutex is unavailable. Newborns exposed to any opioid in utero, including buprenorphine, may experience neonatal opioid withdrawal syndrome (NOWS); this is treatable with supportive hospital care and does not reflect a failure of maternal treatment. The greatest danger to pregnancy is untreated opioid use disorder — withdrawal cycles, overdose, and associated health risks. Continuing or starting MAT during pregnancy is the evidence-based standard of care.

Common misconceptions about Suboxone

Several persistent myths about Suboxone get in the way of people starting treatment. The first is that "you are just trading one addiction for another" — a framing that conflates dependence (a physiological adaptation) with addiction (compulsive use despite harm) and ignores decades of outcome data showing that maintenance buprenorphine saves lives. The second is that Suboxone is a short-term detox medication rather than long-term care; for most patients with moderate-to-severe OUD, months-to-years of maintenance produces materially better outcomes than short tapers. The third is that you should reach some personal milestone before "earning" a taper; decisions about tapering should be clinical, not moral, and based on sustained stability rather than arbitrary deadlines. If any of these ideas are shaping your reluctance to start or stay on MAT, bring them up directly with your prescriber — these are conversations clinicians have every day, and honest discussion generally produces better treatment decisions than silent doubt.

Does Suboxone show up on drug tests?

Standard 5-panel and 10-panel drug screens used by most employers do not detect buprenorphine — those panels target specific substances like amphetamines, cocaine, opiates, PCP, and THC. Buprenorphine requires a specific immunoassay or confirmatory test, and is not included unless specifically ordered. If you are in MAT and concerned about employment testing, it is reasonable to disclose proactively to an occupational health provider under the protections of the Americans with Disabilities Act (ADA); opioid use disorder treated with medication is a protected condition, not a disqualifying one, in most settings. Your Clear Steps Recovery care team can provide a prescriber letter documenting legitimate medical use if you need one for a workplace screening. Note: Suboxone may produce a positive result on tests that specifically screen for buprenorphine, which is expected and appropriate for patients in MAT.

Does Suboxone cause dependence?

Yes — physical dependence on buprenorphine develops with sustained use, meaning that stopping abruptly can cause withdrawal. This is an expected, manageable property of any opioid-receptor medication, not a sign of treatment failure. Dependence is not the same as addiction; addiction is a pattern of compulsive use despite harm, while dependence is a predictable physiological adaptation. When a patient and prescriber eventually decide to taper off Suboxone, it is done gradually over weeks or months to minimize withdrawal, and always with careful attention to relapse risk. Many patients remain on Suboxone indefinitely because the evidence supports long-term maintenance as producing the best outcomes (NIDA, 2024).

What does treatment cost, and is it covered by insurance?

Under the Affordable Care Act and subsequent mental health parity rules, most commercial insurance plans, Medicaid, and Medicare Part D cover buprenorphine products including Suboxone. In New Hampshire, NH Medicaid covers buprenorphine film and tablets with no prior authorization for opioid use disorder treatment in most cases; in Massachusetts, MassHealth provides similar coverage. Cash-pay pricing for the medication alone varies; generic buprenorphine-naloxone tablets are typically less expensive than branded Suboxone film. Visit costs for the prescribing clinician are typically billed separately and covered by the same insurance plan. At Clear Steps Recovery, our admissions team can verify your benefits at no cost and explain what out-of-pocket expenses — if any — to expect before you start. Sliding-scale and community-based options exist for uninsured patients; in NH, The Doorway hubs connect patients to no-cost pathways.

How do I access Suboxone treatment in New Hampshire or Massachusetts?

There are several routes. Any waivered-or-newly-eligible physician, nurse practitioner, or physician assistant can prescribe Suboxone in office-based settings since the 2023 federal rule change. In New Hampshire, you can reach The Doorway NH (dial 2-1-1) for 24/7 access to addiction treatment and MAT referrals. In Massachusetts, the state's Massachusetts Substance Use Helpline (1-800-327-5050) provides confidential referrals. Clear Steps Recovery offers Medication-Assisted Treatment integrated with individual counseling, group therapy, and family support at our Londonderry, NH and Needham, MA outpatient programs. Our clinical team, led by Medical Director Dr. Richard Marasa, provides full assessments, induction support (in-office or telehealth where appropriate), and ongoing management. Insurance coverage varies; most commercial plans, Medicaid (MassHealth in MA, NH Medicaid), and Medicare cover buprenorphine products.

Ready to talk to a clinician?

If you or someone you love is working through opioid use disorder, Clear Steps Recovery offers outpatient MAT including Suboxone in both New Hampshire and Massachusetts. Call (603) 769-8981 for our Londonderry, NH program or (781) 765-0001 for our Needham, MA program — our admissions team answers 24/7 and the conversation is confidential. You can also reach the free SAMHSA National Helpline at 1-800-662-HELP (4357) for 24/7 treatment referral, and 988 (call or text) for any mental health crisis.